RxDoctor Payments Data

Jeanie McCormack, DO

Neurology · Owensboro, KYNPI 1508043274

Payments from drug & device makers

$8,523in general payments, 2019–2025

Across 495 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$783
  • Novartis$513
  • Pfizer$374
  • Lilly USA, LLC$351
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$290%
  • Food & beverage$8,01994%
  • Education$4756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,523 in reported general payments places this provider in the 60th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$184,978
Medicare patients
412
Services billed
16,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b12$121,754
Aimovig AutoinjectorErenumab-Aooe161$121,739
CopaxoneGlatiramer Acetate20$111,948
Nurtec OdtRimegepant Sulfate69$97,406
QuliptaAtogepant73$89,921
UbrelvyUbrogepant58$70,080
Emgality PenGalcanezumab-Gnlm75$64,139
BriviactBrivaracetam36$44,761
BotoxOnabotulinumtoxina31$41,498
AptiomEslicarbazepine Acetate11$19,713
TrileptalOxcarbazepine12$18,432
Lacosamide121$14,457
Keppra XrLevetiracetam12$13,940
Levetiracetam509$13,912
Dalfampridine ErDalfampridine47$11,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Botox$1,820$201,499162 claims
Teva Pharmaceuticals USA, Inc.Copaxone$783$111,94820 claims
PfizerNurtec Odt$374$97,40669 claims
UCB, Inc.Briviact$344$44,76136 claims
Sunovion Pharmaceuticals Inc.Aptiom$99$19,71311 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$66$5,92587 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 neurology providers in Kentucky.

Other neurology in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →